Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
5.95
-0.04 (-0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
6.08
+0.13 (2.18%)
After-hours: Apr 28, 2026, 6:04 PM EDT
Plus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 5.21 | 5.82 | 4.91 | 0.22 | - | |
| Revenue Growth (YoY) | -10.49% | 18.54% | 2093.30% | - | - | |
| Cost of Revenue | 8.38 | 10.58 | 9.69 | 9.7 | 5.32 | |
| Gross Profit | -3.17 | -4.76 | -4.78 | -9.47 | -5.32 | |
| Selling, General & Admin | 12.13 | 9.94 | 8.54 | 10.24 | 6.85 | |
| Operating Expenses | 12.13 | 9.94 | 8.54 | 10.24 | 6.85 | |
| Operating Income | -15.3 | -14.7 | -13.32 | -19.71 | -12.18 | |
| Interest Expense | -0.55 | -0.18 | -0.4 | -0.71 | -0.93 | |
| Interest & Investment Income | 0.12 | 0.27 | 0.4 | 0.15 | 0.02 | |
| Other Non Operating Income (Expenses) | -6.66 | 1.62 | - | 0 | 0.01 | |
| EBT Excluding Unusual Items | -22.39 | -12.98 | -13.32 | -20.28 | -13.08 | |
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.07 | |
| Pretax Income | -22.39 | -12.98 | -13.32 | -20.28 | -13.4 | |
| Earnings From Continuing Operations | -22.39 | -12.98 | -13.32 | -20.28 | -13.4 | |
| Net Income | -22.39 | -12.98 | -13.32 | -20.28 | -13.4 | |
| Net Income to Common | -22.39 | -12.98 | -13.32 | -20.28 | -13.4 | |
| Shares Outstanding (Basic) | 3 | 0 | 0 | 0 | 0 | |
| Shares Outstanding (Diluted) | 3 | 0 | 0 | 0 | 0 | |
| Shares Change (YoY) | 910.35% | 145.18% | 79.45% | 117.18% | 173.02% | |
| EPS (Basic) | -7.19 | -48.86 | -105.99 | -289.58 | -415.63 | |
| EPS (Diluted) | -7.25 | -58.52 | -106.00 | -289.58 | -416.25 | |
| Free Cash Flow | -20.84 | -10.7 | -13.01 | -13.48 | -10.42 | |
| Free Cash Flow Per Share | -6.70 | -34.74 | -103.56 | -192.55 | -323.35 | |
| Gross Margin | -60.73% | -81.66% | -97.23% | - | - | |
| Operating Margin | -293.46% | -252.32% | -271.14% | -8800.00% | - | |
| Profit Margin | -429.43% | -222.84% | -271.04% | -9051.34% | - | |
| Free Cash Flow Margin | -399.81% | -183.72% | -264.83% | -6018.30% | - | |
| EBITDA | -14.85 | -13.82 | -12.69 | -19.09 | -11.78 | |
| EBITDA Margin | -284.92% | -237.34% | -258.35% | - | - | |
| D&A For EBITDA | 0.45 | 0.87 | 0.63 | 0.62 | 0.4 | |
| EBIT | -15.3 | -14.7 | -13.32 | -19.71 | -12.18 | |
| EBIT Margin | -293.46% | -252.32% | -271.14% | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.